Go to the main menu
Skip to content
Go to bottom
REFERENCE LINKING PLATFORM OF KOREA S&T JOURNALS
> Journal Vol & Issue
Journal of Pharmaceutical Investigation
Journal Basic Information
Journal DOI :
The Korean Society of Pharmaceutical Sciences and Technology
Editor in Chief :
Volume & Issues
Volume 15, Issue 4 - Dec 1985
Volume 15, Issue 3 - Sep 1985
Volume 15, Issue 2 - Jun 1985
Volume 15, Issue 1 - Mar 1985
Selecting the target year
Protein Binding of Disopyramide -Displacement by Mono-N-Dealkyl-Disopyramide and Variation with Commerial Source of Alpha-1-Acid Glycoprotein-
Haughey, David B. ; Steinberg, Irving ; Lee, Min-Hwa ;
Journal of Pharmaceutical Investigation, volume 15, issue 1, 1985, Pages 1~7
Previous studies show that the free (unbound) fraction of disopyramide in human serum is drug concentration dependent~ at corresponding serum disopyramide concentrations that are achieved clinically.
, disopyramide free fraction values vary several fold at any given drug concentration in human serum and tend to decrease as serum cocentrations of alpha-I-acid glycoprotein(AAG) incrase.
demonstrates that the free fraction of disopyramide inhuman serum increases almost 2-fold following the addition of
mono-N-dealkyldisopyramide. These studies and others.
prompted the present investigation to characterize the protein binding of disopyramide in human serum and solutions of AAG in the presence of mono-N-dealkyldisopyramide (a major metabolite of, disopyramide) and to determine the utility of using commercially available alpha-I-acid glycoprotein for drug protein binding displacement studies. Because many basic and acidic compounds are known to bind to alpha-I-acid
the present study. was performed to determine whteher commercially available AAG would provide a convenient protein source for such binding studies.
Preparation and Identification of Crystal Modification of Piroxicam
Suh, Jung-Jin ; Kim, Bong-Hee ; Ko, Jung-Gil ;
Journal of Pharmaceutical Investigation, volume 15, issue 1, 1985, Pages 8~14
Data obtained from X-ray diffractometry, thermal analysis, IR spectroscopy and microscopic observation were used for the identification and characterization of four crystalline modifications of piroxicam. form a was crystallized from sodium hydroxide-hydrochloric acid and from c was obtained by crystallization from toluene. Form b and d was crystallized from methanol under the different temperature conditions. Relative rates of dissolution and solubility of four crystal forms of piroxicam in distilled water were measured.
Inclusion Compound of Flurbiprofen with Cyclodextrin
Paik, Wan-Sook ; Young, Jae-Ick ; Kim, Kil-Soo ;
Journal of Pharmaceutical Investigation, volume 15, issue 1, 1985, Pages 15~21
The inclusion of
with flurbiprofen in aqueous phase was investigated by UV absorption and circular dichroism spectroscopies. The inclusion complex in solid powder form were made by the freeze-drying and coprecipitation methods in molar ratio 1:1. The inclusion complex formation was confirmed by infrared absorption spectroscopy. The freeze-drying method was successful in obtaining the inclusion compounds compared with the coprecipitation method. The dissolution of solid flurbiprofen inclusion complex was examined in comparison with those of flurbiprofen alone. The inclusion complex obtained by freeze-drying method increased the dissolution rate.
Influence of Some Sympathetic Blocking Agents on Pressor Actions of Norepinephrine and Angiotensin in Rabbits.
Eun, Chong-Young ;
Journal of Pharmaceutical Investigation, volume 15, issue 1, 1985, Pages 22~31
The influence of some sympathetic blocking agents on pressor actions of norepinephrine and angiotensin was investigated in rabbits. 1. Phentolamine, sympathetic
agent, blocked the pressor action of norepinephrine, but did not affect the pressor action of angiotensin 2. Chlorisondamine, autonomic ganglionic blocking agent, potentiated the both actions of norepinephrine and angiotensin. 3. Guanethidine, bethanidine and debrisoquine, sympathetic neuronal blocking agents, potentiated the action of norepinephrine, while diminished that of angiotensin. 4. Reserpine, norepinephrine depleting agent, increased the pressor response of norepinephrine, but did not influence the pressor action of angiotensin.
Bioavailability of Sustained Release Capsules of Ascorbic Acid in Guina Pigs
Ann, Hyung-Soo ; Park, Jae-Kil ; Han, Chang-Hun ;
Journal of Pharmaceutical Investigation, volume 15, issue 1, 1985, Pages 32~39
Bioavailability studies in guinea pigs and dissolution tests of sustained release capsules of ascorbic acid were investigated comparing with those of solution. The results were as follows; 1. In the dissolution test sustained release capsules released 90% of ascorbic acid after 12 hours, and ascorbic acid in the chewable tablet was dissolved. completely within 10 minutes. 2. In the determination of total ascorbic acid concentration in serum, the area under the curve between 0 and 24 hours
ana the maximum serum concentration
did not show any significant difference between solution and sustained release capsule. The time to the maximum concentration
and the time over
concentration showed significant difference. 3. The time reached to maximum excretion rate
in sustained release capsule was longer than that of solution.
Studies on Stability of Ftorafur
Baik, Chia-Sun ; Choi, Jun-Shik ; Yu, Young-Jong ;
Journal of Pharmaceutical Investigation, volume 15, issue 1, 1985, Pages 40~44
The stability of ftorafur in artificial gastric juice and its major decomposition product were studied quantitatively by the combination of TLC technique and UV-recording spectrophotometry. The decomposition proceeded in first-order reaction. The decomposition rate was accelerated by the increase of temperature. The major decomposition products were identified as 5-fluorouracil. The apparent activation energy for the decomposition was found to he approximately 24.3kcal/mole from Arrhenius plot.